UNSPSC 51144114: Clortermine

This classification denotes a cns stimulant with the molecular formula C10H14ClN, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 4FA88HM3IX, chemically known as 2-chloro-alpha,alpha-dimethylbenzeneethanamine but more generally known as clortermine, which bears US NIH Compound Identifier 25223. European Medicines Agency schedules Clortermine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06768MIG.

UNSPSC 51144114 Clortermine is a Commodity code under which state and local governments procure pharmaceutical products and related health interventions, including naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products distributed through authorized wholesale and direct-to-manufacturer channels. Recent solicitations show procurement focused on emergency response medications, community health supply chains, and bulk pharmaceutical distribution agreements serving public health departments, county health systems, and state employee benefit programs. The issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. Vendors must typically meet federal compliance requirements including Good Manufacturing Practices certification, Drug Supply Chain Security Act adherence, E-Verify employment verification, and federal environmental regulations when FEMA funding is involved.

Recent activity spans multiple states with visible procurement in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023, under a two-year contract with one-year renewal option potentially funded through FEMA. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, gathering market intelligence on direct-to-manufacturer prescription programs for self-insured health plans and state agencies as a precursor to formal RFP development. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP for generic multi-source pharmaceuticals and OTC products on January 20, 2026, with a March 26, 2026 response deadline and July 1, 2026 contract effective date; MMCAP agreements serve participating state and local facilities across multiple states including Oregon, with vendor pricing weighted 75 percent in evaluation and subject to a 3 percent administrative fee on all purchases.